97 results
8-K
EX-10.1
ENTO
Entero Therapeutics Inc.
11 Jul 24
Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds
8:00am
8-K
EX-10.2
ENTO
Entero Therapeutics Inc.
13 May 24
Entry into a Material Definitive Agreement
5:26pm
8-K
EX-10.1
ENTO
Entero Therapeutics Inc.
13 May 24
Entry into a Material Definitive Agreement
5:26pm
10-K
2023 FY
EX-10.53
ENTO
Entero Therapeutics Inc.
Annual report
29 Mar 24
4:16pm
DEFA14A
EX-10.6
ENTO
Entero Therapeutics Inc.
14 Mar 24
Additional proxy soliciting materials
6:10am
DEFA14A
EX-10.1
hng9lgp
14 Mar 24
Additional proxy soliciting materials
6:10am
DEFA14A
EX-10.3
h8kd2
14 Mar 24
Additional proxy soliciting materials
6:10am
DEFA14A
EX-10.2
jwoukc2x7bsvru7of 6o
14 Mar 24
Additional proxy soliciting materials
6:10am
DEFA14A
EX-10.5
2zmhqgbzfiki9uvml3p3
14 Mar 24
Additional proxy soliciting materials
6:10am
DEFA14A
EX-10.4
fc6dd
14 Mar 24
Additional proxy soliciting materials
6:10am
DEFA14A
EX-10.7
p3b z35v6
14 Mar 24
Additional proxy soliciting materials
6:10am
8-K
EX-10.2
o3qmz0wd4 jb
14 Mar 24
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
6:09am
8-K
EX-10.1
8r2qzz8a3oh
14 Mar 24
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
6:09am
8-K
EX-10.5
bin2ci feimrxi
14 Mar 24
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
6:09am
8-K
EX-10.7
5g5qnt2k
14 Mar 24
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
6:09am
8-K
EX-10.6
jr46c2kh7o6
14 Mar 24
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
6:09am
8-K
EX-10.3
22n4zjo0
14 Mar 24
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
6:09am
8-K
EX-10.4
vb9w1f3
14 Mar 24
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
6:09am
8-K
EX-10.1
p80m0r2mjv72 3wsr7
5 Mar 24
First Wave BioPharma, Inc. to raise approximately $4.0 million of Gross Proceeds in Registered Direct Offering
5:26pm
8-K
EX-10.2
k7z19d96kok4g0u7saef
5 Mar 24
First Wave BioPharma, Inc. to raise approximately $4.0 million of Gross Proceeds in Registered Direct Offering
5:26pm